Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has earned an average recommendation of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $24.67.
A number of equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. ValuEngine downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Canaccord Genuity set a $22.00 price objective on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, BidaskClub raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th.
Aquinox Pharmaceuticals (NASDAQ AQXP) remained flat at $$11.42 on Friday. 83,400 shares of the stock were exchanged, compared to its average volume of 67,159. Aquinox Pharmaceuticals has a 12 month low of $9.83 and a 12 month high of $19.97.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings results on Tuesday, August 8th. The company reported ($0.59) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.59). equities research analysts forecast that Aquinox Pharmaceuticals will post -2.29 earnings per share for the current year.
Large investors have recently made changes to their positions in the stock. Archon Partners LLC grew its position in Aquinox Pharmaceuticals by 44.0% in the 2nd quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock worth $253,000 after purchasing an additional 5,500 shares during the last quarter. Alps Advisors Inc. grew its position in Aquinox Pharmaceuticals by 4.7% in the 2nd quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock worth $297,000 after purchasing an additional 939 shares during the last quarter. Bank of New York Mellon Corp grew its position in Aquinox Pharmaceuticals by 16.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after purchasing an additional 3,299 shares during the last quarter. Sphera Funds Management LTD. bought a new position in Aquinox Pharmaceuticals in the 2nd quarter worth about $874,000. Finally, Northern Trust Corp grew its position in Aquinox Pharmaceuticals by 3.3% in the 2nd quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after purchasing an additional 2,691 shares during the last quarter. 95.15% of the stock is owned by institutional investors and hedge funds.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.